{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:01:01Z","timestamp":1763442061840,"version":"3.45.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eururo.2025.06.023","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:22:11Z","timestamp":1753903331000},"page":"633-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V\u2013STORM): A Phase 2, Open-label, Randomised Controlled Trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Christian","family":"Thomas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1052-2692","authenticated-orcid":false,"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.06.023_b0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.023_b0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.06.023_b0015","doi-asserted-by":"crossref","unstructured":"Karpinski MJ, Rahbar K, Bogemann M, et al. Updated prostate cancer risk groups by prostate-specific membrane antigen positron emission tomography prostate cancer molecular imaging standardized evaluation (PPP2): results from an international multicentre registry study. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2025.04.017.","DOI":"10.1016\/j.eururo.2025.04.017"},{"issue":"5 Suppl","key":"10.1016\/j.eururo.2025.06.023_b0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","article-title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration","volume":"43","author":"Tang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.06.023_b0025","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825003987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T04:59:09Z","timestamp":1763441949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825003987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0302283825003987"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.023","relation":{},"ISSN":["0302-2838"],"issn-type":[{"type":"print","value":"0302-2838"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Salvage Metastasis-directed Therapy Versus Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases (PEACE V\u2013STORM): A Phase 2, Open-label, Randomised Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.06.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}